Does neoadjuvant therapy contribute to increased risk in anastomotic leakage of esophageal cancer? A network meta-analysis

Abstract

Aim: Conflicting results have been reported about the impact of neoadjuvant therapy on anastomotic leakage (AL) after esophagectomy. We aimed to unravel the potential effect of neoadjuvant therapy on AL after esophagectomy through a network meta-analysis.

Methods: A Bayesian network meta-analysis was performed by retrieving relevant literature from PubMed, EMbase, The Cochrane Library and Web of Science Core Collection. Randomized clinical trials (RCTs) and retrospective studies (RS) comparing the following treatment modalities were included: neoadjuvant chemoradiation (nCRT), neoadjuvant chemotherapy (nCT), neoadjuvant radiotherapy (nR), neoadjuvant immunochemotherapy (nICT), and surgery alone (SA). Subgroup analyses by radiation dose, examined lymph nodes (ELN), route of reconstruction, site of anastomosis, and surgical approach were also conducted.

Results: A total of 62 studies with 12, 746 patients were included for the present study, among which 17 were RCTs. There were no significantly statistical differences observed among the five treatment modalities in AL for both RCTs (nCRT-nICT: risk ratio 1.51, 95% confidence interval 0.52–4.4; nCT-nICT: 1.71, 0.56–5.08; nICT-nR: 0.79, 0.12–8.02; nICT-SA: 0.59, 0.2–1.84) and RS (nCRT-nICT: odds ratio 1.53, 95% confidence interval 0.84–2.84; nCT-nICT: 1.56, 0.87–2.88; nICT-SA: 0.6, 0.31–1.12; nICT-nR: 1.08, 0.09–36.02). Subgroup analysis revealed that no significant difference in AL was observed among the five treatment modalities except for the impact of nCRT versus nCT (0.21, 0.05–0.73) on AL with a radiation dose ≥41.4 Gy.

Conclusions: Neoadjuvant therapy do not significantly increase the incidence of AL after esophagectomy. Administration of irradiation with a moderate dose is not associated with elevated risk in AL. Clinicians can be less apprehensive about prescribing nCRT.

Keywords

anastomotic leakage / esophageal cancer / neoadjuvant therapy

References

[1] SungH,FerlayJ, SiegelRL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2] EyckBM,van Lanschot JJB,HulshofMCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995-2004.

[3] YangH,LiuH, ChenY, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796-2803.

[4] WatanabeM,OtakeR, KozukiR, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12-20.

[5] SihagS,KuGY, TanKS, et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 2021;161(3):836-843.e1.

[6] MboumiIW,ReddyS, LidorAO. Complications after esophagectomy. Surg Clin N Am. 2019;99(3).

[7] FabbiM,HagensERC, van Berge HenegouwenMI,GisbertzSS. Anastomotic leakage after esophagectomy for esophageal cancer: definitions, diagnostics, and treatment. Dis Esophagus. 2021;34(1):doaa039.

[8] AoyamaT,KazamaK, AtsumiY, et al. Clinical influence of anastomotic leakage on esophageal cancer survival and recurrence. Anticancer Res. 2020;40(1):443-449.

[9] KassisES,Kosinski AS,RossP,KoppesKE,DonahueJM, DanielVC. Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg. 2013;96(6):1919-1926.

[10] HulscherJBF,van Sandick JW,de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662-1669.

[11] van WorkumF,van der Maas J,van den WildenbergFJH, et al. Improved functional results after minimally invasive esophagectomy: intrathoracic versus cervical anastomosis. Ann Thorac Surg. 2017;103(1):267-273.

[12] van HagenP,HulshofMCCM, van LanschotJJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084.

[13] WangH,TangH, FangY, et al. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg. 2021;156(5):444-451.

[14] van HeijlM,van Wijngaarden AKS,LagardeSM,BuschORC,van Lanschot JJB,van Berge HenegouwenMI. Intrathoracic manifestations of cervical anastomotic leaks after transhiatal and transthoracic oesophagectomy. Br J Surg. 2010;97(5):726-731.

[15] StippelDL,TaylanC, SchröderW,BeckurtsKTE,Hölscher AH. Supraventricular tachyarrhythmia as early indicator of a complicated course after esophagectomy. Dis Esophagus. 2005;18(4):267-273.

[16] JonesCE,WatsonTJ. Anastomotic leakage following esophagectomy. Thorac Surg Clin. 2015;25(4):449-459.

[17] KoëterM,van der Sangen MJC,HurkmansCW,LuyerMDP,RuttenHJT, NieuwenhuijzenGAP. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy. Radiat Oncol. 2015;10:59.

[18] KoëterM,Kathiravetpillai N,GooszenJA, et al. Influence of the extent and dose of radiation on complications after neoadjuvant chemoradiation and subsequent esophagectomy with gastric tube reconstruction with a cervical anastomosis. Int J Radiat Oncol Biol Phys. 2017;97(4):813-821.

[19] GronnierC,Tréchot B,DuhamelA, et al. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study. Ann Surg. 2014;260(5):764-770.discussion 770–771.

[20] JinZ,ZhangJ, ChenD, et al. Neoadjuvant chemoradiotherapy, chemotherapy, and radiotherapy do not significantly increase the incidence of anastomotic leakage after esophageal cancer surgery: a meta-analysis. Dis Esophagus. 2022;35(9):doab089.

[21] Vande WalleC,CeelenWP, BoterbergT, et al. Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus. Int J Radiat Oncol Biol Phys. 2012;82(3):e513-519.

[22] NygaardK,HagenS, HansenHS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16(6):1104-1109. discussion 1110.

[23] WilkeTJ,BhirudAR, LinC. A review of the impact of preoperative chemoradiotherapy on outcome and postoperative complications in esophageal cancer patients. Am J Clin Oncol. 2015;38(4):415-421.

[24] HigginsJPT,AltmanDG, GøtzschePC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

[25] SterneJA,Hernán MA,ReevesBC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

[26] ChaimaniA,HigginsJPT, MavridisD,Spyridonos P,SalantiG. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.

[27] CiprianiA,HigginsJPT, GeddesJR,Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130-137.

[28] HigginsJPT,Thompson SG,DeeksJJ,AltmanDG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.

[29] BorensteinM,HigginsJPT, HedgesLV,Rothstein HR. Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Res Synth Meth. 2017;8(1):5-18.

[30] NikolakopoulouA,HigginsJPT, PapakonstantinouT, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.

[31] YangH,FuJ, LiuM, et al. A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis. Natl Med J China. 2012;92(15):1028-1032.

[32] Rajabi MashhadiM,Bagheri R,AbdollahiA, et al. The effect of neoadjuvant therapy on early complications of esophageal cancer surgery. Iran J Otorhinolaryngol. 2015;27(81):279-284.

[33] LvJ,CaoXF, ZhuB,JiL, TaoL,WangDD. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol. 2010;16(13):1649-1654.

[34] BoonstraJJ,KokTC, WijnhovenBP, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181.

[35] TepperJ,KrasnaMJ, NiedzwieckiD, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-1092.

[36] NatsugoeS,OkumuraH, MatsumotoM, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006;19(6):468-472.

[37] BurmeisterBH,Smithers BM,GebskiV, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659-668.

[38] AnF,HuangJ, XieY,ChenS, RongT. A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma. Chin J Oncol. 2003;25(4):376-379.

[39] UrbaSG,Orringer MB,TurrisiA,IannettoniM,Forastiere A,StrawdermanM. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305-313.

[40] BabaM,Natsugoe S,ShimadaM, et al. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 2000;13(2):136-141.

[41] WangYJ,LiKK, XieXF, et al. Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: short-term results of an open-label, randomized, phase II trial. Front Oncol. 2022;12.

[42] YongX,QianlunH, YimingY,Bin L,XingbangW. Clinical trial of carrelizumab injection combined with operation in the treatment of patients with stage II/III esophageal squamous cell carcinoma. Chi J Pharmacol. 2021;37(24):3323-3325.

[43] LiY,ZhouA, LiuS, et al. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: a randomized clinical trial of neoadjuvant therapy for ESCC. BMC Med. 2023;21(1):86.

[44] RohS,Iannettoni MD,KeechJ, et al. Timing of esophagectomy after neoadjuvant chemoradiation therapy affects the incidence of anastomotic leaks. Korean J Thorac Cardiovasc Surg. 2019;52(1):1-8.

[45] ShridharR,Takahashi C,HustonJ,DoepkerMP,Meredith KL. Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer. J Gastrointest Oncol. 2018;9(5):894-902.

[46] NederlofN,SlamanAE, van HagenP, et al. Using the comprehensive complication index to assess the impact of neoadjuvant chemoradiotherapy on complication severity after esophagectomy for cancer. Ann Surg Oncol. 2016;23(12):3964-3971.

[47] HamaiY,HiharaJ, TaomotoJ,Yamakita I,IbukiY,OkadaM. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. Dis Esophagus. 2015;28(4):358-364.

[48] BakhosC,OyasijiT, ElmadhunN, et al. Feasibility of minimally invasive esophagectomy after neoadjuvant chemoradiation. J Laparoendosc Adv Surg Tech A. 2014;24(10):688-692.

[49] BoschDJ,MuijsCT, MulVEM, et al. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Ann Surg Oncol. 2014;21(2):605-611.

[50] FujiwaraY,Yoshikawa R,KamikonyaN, et al. Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Mol Clin Oncol. 2013;1(4):773-779.

[51] Ben-DavidK,Rossidis G,ZloteckiRA, et al. Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy. Annals of surgical oncology. 2011;18(12).

[52] MerrittRE,WhyteRI, D’ArcyNT,HoangCD,ShragerJB. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg. 2011;92(6):2034-2040.

[53] XiaoX,YangYS, ZengXX, et al. The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer. Eur J Cardiothorac Surg. 2022;62(1).

[54] HongZN,GaoL, WengK,Huang Z,HanW,KangM. Safety and feasibility of esophagectomy following combined immunotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score matching analysis. Front Immunol. 2022;13:836338.

[55] PucherPH,RahmanSA, WalkerRC, et al. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: inverse propensity score weighted analysis. Eur J Surg Oncol. 2020;46(12):2248-2256.

[56] ViswanathanMP,Suresh Kumar D,Arul KumarG,Sakthi Usha DeviJ,Balamurugan TD. Analysis of carcinoma of the esophagus patients between upfront surgery vs. neoadjuvant therapy followed by surgery. Indian J Surg. 2020;82(6):1026-1030.

[57] ZhengY,LiY, LiuX, et al. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer. 2019;10(5):1097-1102.

[58] MaS,YanT, LiuD, et al. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma. Thorac Cancer. 2018;9(2):310-315.

[59] MatsudaS,TsubosaY, SatoH, et al. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Dis Esophagus. 2017;30(2):1-8.

[60] FujiwaraY,LeeS, KishidaS, et al. Safety and feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy for esophageal cancer. Surg Today. 2017;47(11):1356-1360.

[61] AchiamMP,JensenLB, LarssonH, et al. Comparative investigation of postoperative complications in patients with gastroesophageal junction cancer treated with preoperative chemotherapy or surgery alone. Scand J Surg. 2016;105(1):22-28.

[62] AsakaS,Shimakawa T,YamaguchiK, et al. The influence of neoadjuvant chemotherapy with docetaxel, nedaplatin and 5-fluorouracil after esophagectomy. Antican Res. 2016;36(11).

[63] SpectorR,ZhengY, YeapBY, et al. The 3-hole minimally invasive esophagectomy: a safe procedure following neoadjuvant chemotherapy and radiation. Semin Thorac Cardiovasc Surg. 2015;27(2):205-215.

[64] CaoXF,HeXT, JiL,XiaoJ, LvJ. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 2009;22(6):477-481.

[65] HallidayBP,Skipworth RJ,WallL, et al. Neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophago-gastric junction: a six-year experience. Int Semin Surg Oncol. 2007;4:24.

[66] KelleyST,CoppolaD, KarlRC. Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy. J Gastrointest Surg. 2004;8(3):227-231. discussion 231–232.

[67] XuL,WeiXF, LiCJ, et al. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Front Immunol. 2022;13:1052542.

[68] HardackerTJ,CeppaD, OkerekeI, et al. Treatment of clinical T2N0M0 esophageal cancer. Ann Surg Oncol. 2014;21(12):3739-3743.

[69] ZhangJQ,HookerCM, BrockMV, et al. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann Thorac Surg. 2012;93(2):429-435. discussion 436–437.

[70] ParkSY,HongMH, KimHR, et al. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. J Thorac Dis. 2020;12(11):6426-6434.

[71] JingSW,ZhaiC, ZhangW, et al. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: a propensity score matching. Front Immunol. 2022;13:970534.

[72] QiaoY,ZhaoC, LiX, et al. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy. Front Immunol. 2022;13:953229.

[73] HongZ,XuJ, ChenZ, et al. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study. Int J Surg. 2023;109(8):2168-2178.

[74] ZhaoJ,HaoS, TianJ,Li Y,HanD. Comparison of neoadjuvant immunotherapy plus chemotherapy versus neoadjuvant chemoradiotherapy for patients with esophageal squamous cell carcinoma: a propensity score matching study. J Inflamm Res. 2023;16:3351-3363.

[75] ZhouRQ,LuoJ, LiLJ,DuM, WuQC. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study. BMC Surg. 2023;23(1):114.

[76] HanD,TianJ, ZhaoJ,Hao S. Optimal treatment strategies for resectable locally advanced esophageal squamous cell carcinoma: a real-world triple cohort analysis using propensity score matching. Int J Gen Med. 2023;16:5467-5479.

[77] ZhangB,ZhaoH, WuX, et al. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer. Front Immunol. 2023;14.

[78] NevoY,TankelJ, ZhaoH, et al. Influence of neoadjuvant immunotherapy-chemotherapy on perioperative outcomes in locally advanced esophageal adenocarcinoma. Ann Surg Oncol. Published online March 26,2024.

[79] El-SouraniN,MiftodeS, AlfarawanF,Troja A,BockhornM. Risk factors and effect of intrathoracic anastomotic leakage after esophagectomy for underlying malignancy—a ten-year analysis at a tertiary university centre. Clin Pract. 2022;12(5):782-787.

[80] GaoW,WangM, SuP,ZhangF, HuangC,Tian Z. Risk factors of cervical anastomotic leakage after McKeown minimally invasive esophagectomy: focus on preoperative and intraoperative lung function. Ann Thorac Cardiovasc Surg. 2021;27(2):75-83.

[81] EscofetX,Manjunath A,TwineC,HavardTJ,ClarkGW, LewisWG. Prevalence and outcome of esophagogastric anastomotic leak after esophagectomy in a UK regional cancer network. Dis Esophagus. 2010;23(2):112-116.

[82] JiangH,HuaR, SunY, et al. Risk factors for anastomotic complications after radical McKeown esophagectomy. Ann Thorac Surg. 2021;112(3):944-951.

[83] AoyamaT,AtsumiY, HaraK, et al. Risk factors for postoperative anastomosis leak after esophagectomy for esophageal cancer. In vivo (Athens, Greece). 2020;34(2).

[84] SimitianGS,HallDJ, LeversonG, et al. Consequences of anastomotic leaks after minimally invasive esophagectomy: A single-center experience. Surg Open Sci 2022;11.

[85] IpB,NgKT, PackerS,Paterson-Brown S,CouperGW. High serum lactate as an adjunct in the early prediction of anastomotic leak following oesophagectomy. Int J Surg (Lond, Engl). 2017;46.

[86] BartellaI,BrunnerS, SchiffmannLM, et al. Clinical utility and applicability of the Esophagus Complication Consensus Group’ (ECCG) classification of anastomotic leakage following hybrid Ivor-Lewis esophagectomy. Langenbecks Arch Surg. 2023;408(1):258.

[87] RiM,Tzortzakakis A,SotirovaI, et al. CRP as an early indicator for anastomotic leakage after esophagectomy for cancer: a single tertiary gastro-esophageal center study. Langenbecks Arch Surg. 2023;408(1):436.

[88] NguyenDT,DatTQ, ThongDQ,Hai NV,BacNH,LongVD. Role of indocyanine green fluorescence imaging for evaluating blood supply in the gastric conduit via the substernal route after McKeown minimally invasive esophagectomy. J Gastrointest Surg. 2024;28(4):351-358.

[89] AjaniJA,D’Amico TA,BentremDJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393-422.

[90] van KootenRT,VoetenDM, SteyerbergEW, et al. Patient-related prognostic factors for anastomotic leakage, major complications, and short-ter. mortality following esophagectomy for cancer: a systematic review and meta-analyses. Ann Surg Oncol. 2022;29(2):1358-1373.

[91] WrightCD,Kucharczuk JC,O’BrienSM,GrabJD,AllenMS,Society of Thoracic Surgeons General Thoracic Surgery Database. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg. 2009;137(3):587-595. discussion 596.

[92] van der WilkBJ,EyckBM, LagardeSM, et al. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis. 2019;11(Suppl 5):S621-S631.

[93] HerzbergJ,StrateT, GurayaSY,Honarpisheh H. Risk factors for anastomotic leakage after surgical resections for esophageal cancer. Langenbecks Arch Surg. 2021;406(6):1859-1866.

[94] SundeB,EricsonJ, KumagaiK, et al. Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction. Dis Esophagus. 2016;29(5):442-447.

[95] LiuWM,FowlerDW, SmithP,Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115-123.

[96] RamakrishnanR,Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother. 2013;62(3):405-410.

[97] ReynoldsJV,RaviN, HollywoodD, et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg. 2006;132(3):549-555.

[98] BiertJ,WobbesT, HoogenhoutJ,de Man B,HendriksT. Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon. Radiother Oncol. 1996;41(3):257-262.

[99] ChanML,HsiehCC, WangCW,Huang MH,HsuWH,HsuHS. Reconstruction after esophagectomy for esophageal cancer: retrosternal or posterior mediastinal route? J Chin Med Assoc. 2011;74(11):505-510.

[100] ZhengYZ,DaiSQ, LiW, et al. Comparison between different reconstruction routes in esophageal squamous cell carcinoma. World J Gastroenterol. 2012;18(39):5616-5621.

[101] HölscherAH,Vallböhmer D,BrabenderJ. The prevention and management of perioperative complications. Best Pract Res Clin Gastroenterol. 2006;20(5):907-923.

[102] ReavisKM. The esophageal anastomosis: how improving blood supply affects leak rate. J Gastrointest Surg. 2009;13(9):1558-1560.

RIGHTS & PERMISSIONS

2024 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.